Editorial Policies

Aims & Scope

The European Journal of Innovative Medical Research (EURJIMR) is an international, peer-reviewed open-access journal dedicated to advancing clinical and experimental medical sciences. The journal publishes original research, reviews, case reports, brief communications, and editorials across all medical and surgical specialties. EURJIMR prioritizes methodological rigor, ethical integrity, and scientific clarity, aiming to serve clinicians, researchers, and interdisciplinary scholars committed to improving patient care and public health. Manuscripts that introduce innovative approaches, address diagnostic or therapeutic challenges, or offer substantial translational value are particularly encouraged.

Editorial Structure

Editor-in-Chief

Responsible for the overall editorial vision, policy implementation, and final decisions on manuscripts.

Associate Editors

Responsible for the editorial vision, policy implementation, and final decisions on manuscripts.

Section Editors

Oversee submissions within their specialty areas, assign suitable reviewers, guide the peer-review process, and recommend editorial decisions.

Editorial Board (in Recruitment)

Composed of recognized experts across medical disciplines who provide scientific guidance, contribute to peer review, and support the journal’s academic standards.

Scientific Advisors (in Recruitment)

Serve as senior consultants offering strategic advice regarding journal development, ethical standards, and long-term editorial quality.

Editorial Workflow

EURJIMR adheres to a transparent, standardized editorial process aligned with DOAJ, TR Dizin, COPE, and Web of Science guidelines.

3.1 Submission

Authors submit manuscripts through the OJS platform. All submissions must comply with journal formatting, ethical standards, and reporting guidelines.

3.2 Technical Check

The editorial office performs initial screening for completeness, formatting, adherence to submission guidelines, figure quality, references, and required documents (ethics approval, informed consent, conflict of interest statements).

3.3 Plagiarism Screening

Every manuscript undergoes similarity analysis using iThenticate or intihal.net. Submissions containing excessive overlap, unattributed material, or suspected misconduct are rejected or investigated according to COPE procedures.

3.4 Assignment to Section Editor

Qualified Section Editors are assigned based on subject area, ensuring independence and avoidance of conflicts of interest.

3.5 Reviewer Invitation

At least two independent expert reviewers are selected. Reviewers are chosen based on expertise, publication record, and absence of conflicts of interest.

3.6 First Decision

After receiving reviewer reports, the Section Editor synthesizes the evaluations and recommends a decision (accept, minor revision, major revision, or reject). The Editor-in-Chief issues the official decision.

3.7 Revision Rounds

Authors are invited to revise their manuscripts in alignment with reviewer and editor comments. Revised submissions undergo reassessment, which may include additional review cycles.

3.8 Final Decision

The Editor-in-Chief confirms the final acceptance based on scientific merit, originality, ethical compliance, and reviewer feedback.

3.9 Copyediting & Production

Accepted manuscripts proceed to professional language editing, technical editing, layout preparation, figure verification, and metadata validation.

3.10 DOI Registration

Each published article receives a unique Crossref DOI, ensuring permanent identification and global discoverability.

3.11 Online Publication

Articles are published online as part of scheduled issues. EURJIMR supports continuous publication within each issue period.

Authorship & Contributorship

EURJIMR follows the ICMJE Recommendations (Defining the Role of Authors and Contributors) to ensure that authorship is assigned responsibly and transparently.

4.1 ICMJE Authorship Criteria

All four criteria must be met:

  1. Substantial contributions to conception/design, data acquisition, or data analysis and interpretation.

  2. Drafting the article or critically revising it.

  3. Final approval of the version to be published.

  4. Agreement to be accountable for all aspects of the work.

4.2 CRediT Taxonomy

Authors must specify their contributions according to the CRediT (Contributor Roles Taxonomy), including roles such as conceptualization, methodology, data curation, writing, supervision, and funding acquisition.

4.3 ORCID Requirement

All authors are required to provide a valid ORCID iD to ensure unambiguous attribution and persistent scholarly identity.

Conflict of Interest (COI) Policy

Transparency is essential for maintaining trust in the scholarly record.

5.1 Authors

Authors must disclose all financial and non-financial relationships, funding sources, institutional affiliations, or personal connections that may influence the research.

5.2 Reviewers

Reviewers must decline invitations if personal, academic, or financial relationships could bias their judgment. Reviewers must not use unpublished data for personal advantage.

5.3 Editors

Editors must recuse themselves from handling manuscripts in which they have personal, professional, or institutional conflicts. In such cases, an alternative Section Editor or Editorial Board member is assigned.

5.4 Handling Editor Reassignment

When a conflict of interest is identified—especially relevant to TR Dizin requirements—the manuscript is immediately reassigned to a qualified editor with no conflict, and the reassignment is documented in the editorial history.

Ethical Considerations

6.1 Human Subjects Research

Studies involving human participants must comply with the Declaration of Helsinki. Ethics committee approval and informed consent are mandatory and must be explicitly stated.

6.2 Animal Research

Animal studies must follow internationally accepted standards for care and use, and approval from institutional animal ethics committees is required.

6.3 Clinical Trial Registration

Prospective registration in a recognized registry (e.g., ClinicalTrials.gov, EU-CTR) is required for all clinical trials.

6.4 Informed Consent

Case reports, images, and identifiable data require written informed consent from the patient or legal guardian.

6.5 Data Availability

Authors must state the availability of data, including conditions for access, repository information, and any restrictions.

Misconduct Policy

EURJIMR adheres to the COPE Core Practices and handles ethical concerns with full transparency.

Misconduct includes but is not limited to:

  • Plagiarism (including self-plagiarism)

  • Data fabrication or falsification

  • Redundant or duplicate publication

  • Salami slicing

  • Manipulation of images, figures, or data

  • Improper authorship assignment

  • Failure to disclose conflicts of interest

Cases of suspected misconduct are evaluated using the relevant COPE Flowcharts, and appropriate actions range from manuscript rejection to formal retraction.

Correction & Retraction Policy

8.1 Erratum

Issued when the publisher introduces an error during production (e.g., typesetting mistakes).

8.2 Corrigendum

Issued when authors report a significant error that affects but does not invalidate the scientific record.

8.3 Retraction

Reserved for publications with serious ethical breaches, falsified data, unethical research, or major errors invalidating conclusions. Retractions follow COPE Retraction Guidelines and remain linked to the original article.

8.4 Expression of Concern

Published when an investigation is ongoing and serious doubts exist regarding the integrity of a manuscript.